Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. Click here to read more.

Acumatica has announced the general availability of its 2025 R2 ERP Platform. The R2 release features new and updated enhancements that improve usability, ...

Vertex has begun a full-court press for Journavx, enlisting NBA All-Star Jayson Tatum to discuss his use of the new ...

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of ...

Vertex Minerals (ASX:VTX) is still in the early stages of developing its underground mine, and while the production ramp-up was slowed by delays in high-voltage equipment delivery and commissioning, ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 23.6% in the past six months, mainly due to recent pipeline ...

Vertex Pharmaceuticals (VRTX) has outperformed the market over the past 15 years by 4.73% on an annualized basis producing an average annual return of 17.22%. Currently, Vertex Pharmaceuticals has a ...

Vertex Pharmaceuticals (VRTX) announced that the FDA has granted breakthrough therapy designation to povetacicept for the treatment of IgAN. Pove ...

The DP World Tour season is just heating up with multiple PGA Tour golfers now available to compete in some of its biggest tournaments. Traveling to the K Club for this week's Irish Open and Wentworth ...

MANILA, Philippines — President Ferdinand Marcos Jr. on Monday said his office is already drafting the executive order that will create an independent commission tasked with investigating the ...